Andrew Weinberg

Company: AgonOx

Job title: President & Chief Scientific Officer

Seminars:

Unveiling Novel Approaches to Expanding Tumor- Reactive T-Cells & Reducing Bystander T-Cells 2:30 pm

Sorting CD8 TIL for CD39 and CD103 prior to expansion enhances for tumor reactivity This selected expanded TIL has clinical activity in late-stage cancer patientsRead more

day: Conference Day One - Track B - PM